Although IL-17 is overexpressed in IBD patients, the IL-17A neutralizing antibody (secukinumab and ixekizumab) and the IL-17A receptor neutralizing antibody (brodalumab) are not effective in CD patients, and some patients have adverse reactions (133–135). The gene discussed is IL17A; the disease is inflammatory bowel disease.